• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022

    2/14/23 6:00:00 AM ET
    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PKI alert in real time by email
    • Fourth quarter revenue from continuing operations of $741 million; (28)% reported growth; (23)% organic growth; 8% non-COVID organic growth
    • Combined* total fourth quarter revenue of $1,089 million; 8% combined non-COVID organic growth
    • Fourth quarter GAAP EPS from continuing operations of $0.85; combined adjusted EPS of $1.70
    • Initiates Full Year 2023 Guidance

    PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today reported financial results for the fourth quarter and full year ended January 1, 2023.

    Fourth Quarter 2022

    The Company reported GAAP earnings per share from continuing operations of $0.85, as compared to GAAP earnings per share from continuing operations of $1.45 in the same period a year ago. GAAP revenue for the quarter from continuing operations was $741 million, as compared to $1,028 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $137 million, as compared to $300 million for the same period a year ago. GAAP operating profit margin from continuing operations was 18.5% as a percentage of revenue, as compared to 29.2% in the same period a year ago.

    Adjusted operating income from continuing operations was $240 million, as compared to $432 million for the same period a year ago. Adjusted operating profit margin from continuing operations was 32.3% as a percentage of revenue, as compared to 42.0% in the same period a year ago.

    Combined adjusted earnings per share for the quarter was $1.70, as compared to $2.56 in the same period a year ago. Combined adjusted revenue for the quarter was $1,089 million, as compared to $1,365 million in the same period a year ago. Combined adjusted operating income for the quarter was $298 million, as compared to $459 million for the same period a year ago. Combined adjusted operating profit margin was 27.3% as a percentage of adjusted revenue, as compared to 33.6% in the same period a year ago.

    Full Year 2022

    The Company reported GAAP earnings per share from continuing operations of $4.13 in 2022, as compared to GAAP earnings per share from continuing operations of $7.62 in 2021. GAAP revenue from continuing operations for the year was $3,312 million, as compared to $3,828 million in 2021. GAAP operating income from continuing operations for the year was $743 million, as compared to $1,258 million in 2021. GAAP operating profit margin from continuing operations was 22.4% as a percentage of revenue, as compared to 32.9% in 2021.

    Adjusted operating income from continuing operations for the year was $1,212 million, as compared to $1,637 million in 2021. Adjusted operating profit margin from continuing operations was 36.6% as a percentage of revenue, as compared to 42.7% in 2021.

    Combined adjusted earnings per share for the year was $7.95, as compared to $11.36 in 2021. Combined adjusted revenue for the year was $4,611 million, as compared to $5,070 million in 2021. Combined adjusted operating income for the year was $1,381 million, as compared to $1,771 million in 2021. Combined adjusted operating profit margin was 30.0% as a percentage of adjusted revenue, as compared to 34.9% in 2021.

    Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

    *Combined financial metrics are defined as the combination of continuing operations and discontinued operations. Discontinued operations consist of the Applied, Food and Enterprise Services (AES) businesses currently held for sale.

    "2022 was an excellent year for the Company, both operationally and financially, setting us up extremely well to take the next exciting step in our corporate journey by soon separating into two standalone companies," said Prahlad Singh, president and chief executive officer of PerkinElmer. "In 2023, we enter into the next chapter in our history which will uniquely focus on providing breakthrough scientific tools to fuel our customers' development and delivery of the next generation of novel therapies and diagnostics."

    Financial Overview by Reporting Segment for the Fourth Quarter and Full Year 2022

    Discovery & Analytical Solutions Continuing Operations

    • Fourth quarter 2022 revenue was $347 million, as compared to $318 million in the same period a year ago. Reported revenue increased 9% and organic revenue increased 13% as compared to the same period a year ago.
    • Full year revenue was $1,293 million, as compared to $898 million in 2021. Reported revenue increased 44% and organic revenue increased 15% as compared to 2021.
    • Fourth quarter 2022 segment operating income was $146 million, as compared to $117 million for the same period a year ago. Segment operating profit margin was 41.9% as a percentage of revenue, as compared to 36.9% in the same period a year ago.
    • Full year 2022 segment operating income was $503 million, as compared to $282 million in 2021. Full year segment operating profit margin was 38.9% as a percentage of revenue, as compared to 31.4% in 2021.

    Discovery & Analytical Solutions Combined* Operations

    • Fourth quarter 2022 combined revenue was $695 million, as compared to $655 million in the same period a year ago. Combined revenue increased 6% and combined organic revenue increased 11% as compared to the same period a year ago.
    • Full year combined revenue was $2,591 million, as compared to $2,137 million in 2021. Combined reported revenue increased 21% and organic revenue increased 12% as compared to 2021.
    • Fourth quarter 2022 combined segment operating income was $204 million, as compared to $144 million for the same period a year ago. Combined segment operating profit margin was 29.3% as a percentage of revenue, as compared to 22.0% in the same period a year ago.
    • Full year combined segment operating income was $673 million, as compared to $415 million in 2021. Full year combined segment operating profit margin was 26.0% as a percentage of revenue, as compared to 19.4% in 2021.

    Diagnostics

    • Fourth quarter 2022 revenue was $394 million, as compared to $710 million for the same period a year ago. Reported revenue decreased 44% and organic revenue decreased 39% as compared to the same period a year ago.
    • Full year revenue was $2,020 million, as compared to $2,933 million in 2021. Reported revenue decreased 31% and organic revenue decreased 29% as compared to 2021.
    • Fourth quarter 2022 segment operating income was $113 million, as compared to $335 million for the same period a year ago. Segment operating profit margin was 28.7% as a percentage of revenue, as compared to 47.1% in the same period a year ago.
    • Full year segment operating income was $782 million, as compared to $1,433 million in 2021. Full year segment operating profit margin was 38.7% as a percentage of revenue, as compared to 48.9% in 2021.

    Initiates Full Year 2023 Guidance

    For the full year 2023, the Company forecasts total revenue from continuing operations of $2.94 billion and adjusted earnings per share of $5.05. This guidance assumes no contribution from COVID related revenues.

    Guidance for the full year 2023 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

    Webcast Information

    The Company will discuss its fourth quarter and full year 2022 results and its outlook for business trends during a webcast on February 14, 2023, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, ir.perkinelmer.com.

    Use of Non-GAAP Financial Measures

    In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates", "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, such as the divestiture of the Applied, Food and Enterprise Services businesses, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdom's withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    About PerkinElmer

    PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $4.6 billion1 in 2022, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.

    1Includes the combined revenue of continuing operations and discontinued operations

    PerkinElmer, Inc. and Subsidiaries

    CONDENSED CONSOLIDATED INCOME STATEMENTS

     
     

    Three Months Ended

    Twelve Months Ended

    (In thousands, except per share data)

    January 1, 2023

    January 2, 2022

    January 1, 2023

    January 2, 2022

     
     
    Revenue

    $

    741,214

     

    $

    1,027,910

     

    $

    3,311,822

     

    $

    3,827,808

     

     
    Cost of revenue

     

    304,884

     

     

    384,114

     

     

    1,321,992

     

     

    1,393,821

     

    Selling, general and administrative expenses

     

    244,325

     

     

    283,365

     

     

    1,025,514

     

     

    975,193

     

    Research and development expenses

     

    54,536

     

     

    60,584

     

     

    221,617

     

     

    200,337

     

     
    Operating income from continuing operations

     

    137,469

     

     

    299,847

     

     

    742,699

     

     

    1,258,457

     

     
    Interest income

     

    (1,565

    )

     

    (919

    )

     

    (3,589

    )

     

    (2,241

    )

    Interest expense

     

    22,508

     

     

    27,721

     

     

    103,955

     

     

    102,128

     

    Change in fair value of financial securities

     

    1,433

     

     

    (2,419

    )

     

    15,754

     

     

    (10,985

    )

    Other (income) expense, net

     

    (23,354

    )

     

    (24,240

    )

     

    (25,258

    )

     

    (34,027

    )

     
    Income from continuing operations, before income taxes

     

    138,447

     

     

    299,704

     

     

    651,837

     

     

    1,203,582

     

     
    Provision for income taxes

     

    30,950

     

     

    115,615

     

     

    129,161

     

     

    314,146

     

     
    Income from continuing operations

     

    107,497

     

     

    184,089

     

     

    522,676

     

     

    889,436

     

     
    Income from discontinued operations, before income taxes

     

    37,600

     

     

    11,975

     

     

    73,604

     

     

    76,304

     

    Provision for income taxes on discontinued operations and dispositions

     

    7,439

     

     

    5,880

     

     

    17,101

     

     

    22,583

     

     
    Income from discontinued operations and dispositions

     

    30,161

     

     

    6,095

     

     

    56,503

     

     

    53,721

     

     
    Net income

    $

    137,658

     

    $

    190,184

     

    $

    579,179

     

    $

    943,157

     

     
     
    Diluted earnings per share:
    Income from continuing operations

    $

    0.85

     

    $

    1.45

     

    $

    4.13

     

    $

    7.62

     

     
    Income from discontinued operations and dispositions

     

    0.24

     

     

    0.05

     

     

    0.45

     

     

    0.46

     

     
    Net income

    $

    1.09

     

    $

    1.50

     

    $

    4.58

     

    $

    8.08

     

     
     
    Weighted average diluted shares of common stock outstanding

     

    126,476

     

     

    126,715

     

     

    126,426

     

     

    116,674

     

     
     

    ABOVE PREPARED IN ACCORDANCE WITH GAAP

     
     
    Additional Supplemental Information (1):
    (per share, continuing operations)
     
    GAAP EPS from continuing operations

    $

    0.85

     

    $

    1.45

     

    $

    4.13

     

    $

    7.62

     

    Amortization of intangible assets

     

    0.71

     

     

    0.77

     

     

    2.93

     

     

    2.20

     

    Debt extinguishment costs

     

    (0.02

    )

     

    -

     

     

    (0.02

    )

     

    -

     

    Purchase accounting adjustments

     

    0.00

     

     

    0.18

     

     

    0.36

     

     

    0.35

     

    Acquisition and divestiture-related costs

     

    0.11

     

     

    0.07

     

     

    0.32

     

     

    0.69

     

    Change in fair value of financial securities

     

    0.01

     

     

    (0.02

    )

     

    0.12

     

     

    (0.09

    )

    Asset impairment

     

    -

     

     

    -

     

     

    -

     

     

    0.03

     

    Significant litigation matters and settlements

     

    0.00

     

     

    0.00

     

     

    (0.00

    )

     

    0.00

     

    Disposition of businesses and assets, net

     

    (0.02

    )

     

    -

     

     

    (0.02

    )

     

    (0.02

    )

    Mark to market on postretirement benefits

     

    (0.18

    )

     

    (0.18

    )

     

    (0.18

    )

     

    (0.20

    )

    Restructuring and other, net

     

    (0.01

    )

     

    0.03

     

     

    0.11

     

     

    0.12

     

    Tax on above items

     

    (0.07

    )

     

    (0.17

    )

     

    (0.84

    )

     

    (0.66

    )

    Significant tax items

     

    0.04

     

     

    0.29

     

     

    0.02

     

     

    0.44

     

    Adjusted EPS from Continuing Operations

     

    1.41

     

     

    2.42

     

     

    6.92

     

     

    10.49

     

     
    GAAP EPS from discontinued operations

    $

    0.24

     

    $

    0.05

     

    $

    0.45

     

    $

    0.46

     

    Amortization of intangible assets included in discontinued operations

     

    -

     

     

    0.06

     

     

    0.13

     

     

    0.29

     

    Purchase accounting adjustments

     

    -

     

     

    0.00

     

     

    0.00

     

     

    0.00

     

    Acquisition and divestiture-related costs included in discontinued operations

     

    0.24

     

     

    0.07

     

     

    0.61

     

     

    0.20

     

    Significant litigation matters and settlements

     

    -

     

     

    0.00

     

     

    -

     

     

    0.00

     

    Mark to market on postretirement benefits

     

    (0.05

    )

     

    (0.01

    )

     

    (0.05

    )

     

    (0.01

    )

    Restructuring and other, net included in discontinued operations

     

    (0.00

    )

     

    (0.00

    )

     

    0.10

     

     

    0.02

     

    Addback depreciation expense on assets held for sale

     

    (0.03

    )

     

    -

     

     

    (0.05

    )

     

    -

     

    Tax on above items

     

    (0.12

    )

     

    (0.03

    )

     

    (0.17

    )

     

    (0.09

    )

    Less non-AES income tax items in discontinued operations

     

    0.00

     

     

    0.00

     

     

    0.00

     

     

    0.00

     

    Adjusted EPS from AES

    $

    0.28

     

    $

    0.14

     

    $

    1.03

     

    $

    0.87

     

     
    Combined Adjusted EPS including the results of AES

    $

    1.70

    $

    2.56

     

    $

    7.95

     

    $

    11.36

     

     
    (1) amounts may not sum due to rounding
     
     
    PerkinElmer, Inc. and Subsidiaries

    REVENUE AND OPERATING INCOME (LOSS)

     
     
     

    Three Months Ended

    Twelve Months Ended

    (In thousands, except percentages)

    January 1, 2023

    January 2, 2022

    January 1, 2023

    January 2, 2022

     
     
    Adjusted Revenue and Operating Income
     
    Reported revenue

    741,214

     

    1,027,910

     

    3,311,822

     

    3,827,808

     

    Revenue purchase accounting adjustments

    205

     

    202

     

    814

     

    2,648

     

    Adjusted revenue

    741,419

     

    1,028,112

     

    3,312,636

     

    3,830,456

     

     
    Reported operating income from continued operations

    137,469

     

    299,847

     

    742,699

     

    1,258,457

     

    OP%

    18.5

    %

    29.2

    %

    22.4

    %

    32.9

    %

    Amortization of intangible assets

    90,169

     

    97,923

     

    370,638

     

    256,569

     

    Purchase accounting adjustments

    87

     

    22,186

     

    45,681

     

    40,993

     

    Acquisition and divestiture-related costs

    13,961

     

    8,429

     

    39,826

     

    62,760

     

    Asset impairment

    -

     

    -

     

    -

     

    3,868

     

    Significant litigation matters and settlements

    5

     

    2

     

    (627

    )

    2

     

    Restructuring and other, net

    (1,863

    )

    3,841

     

    13,580

     

    14,358

     

    Adjusted operating income

    239,828

     

    432,228

     

    1,211,797

     

    1,637,007

     

    OP%

    32.3

    %

    42.0

    %

    36.6

    %

    42.7

    %

     
    Segment Revenue and Segment Operating Income
     
    DAS

    347,425

     

    318,498

     

    1,292,909

     

    897,718

     

    Diagnostics

    393,994

     

    709,614

     

    2,019,727

     

    2,932,738

     

    Revenue purchase accounting adjustments

    (205

    )

    (202

    )

    (814

    )

    (2,648

    )

    Reported revenue

    741,214

     

    1,027,910

     

    3,311,822

     

    3,827,808

     

     
     
    DAS

    145,582

     

    117,388

     

    503,243

     

    281,602

     

    41.9

    %

    36.9

    %

    38.9

    %

    31.4

    %

    Diagnostics

    113,004

     

    334,540

     

    781,985

     

    1,432,769

     

    28.7

    %

    47.1

    %

    38.7

    %

    48.9

    %

    Corporate

    (18,758

    )

    (19,700

    )

    (73,431

    )

    (77,364

    )

    Subtotal reportable segments

    239,828

     

    432,228

     

    1,211,797

     

    1,637,007

     

     
    Amortization of intangible assets

    (90,169

    )

    (97,923

    )

    (370,638

    )

    (256,569

    )

    Purchase accounting adjustments

    (87

    )

    (22,186

    )

    (45,681

    )

    (40,993

    )

    Acquisition and divestiture-related costs

    (13,961

    )

    (8,429

    )

    (39,826

    )

    (62,760

    )

    Asset impairment

    -

     

    -

     

    -

     

    (3,868

    )

    Significant litigation matters and settlements

    (5

    )

    (2

    )

    627

     

    (2

    )

    Restructuring and other, net

    1,863

     

    (3,841

    )

    (13,580

    )

    (14,358

    )

    Reported operating income from continued operations

    137,469

     

    299,847

     

    742,699

     

    1,258,457

     

     
     

    REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

     
    PerkinElmer, Inc. and Subsidiaries

    REVENUE AND OPERATING INCOME (LOSS)

     
     
     

    Three Months Ended

    Twelve Months Ended

    (In thousands, except percentages)

    January 1, 2023

    January 2, 2022

    January 1, 2023

    January 2, 2022

     
     
    Adjusted Revenue and Operating Income Combined with AES
     
    Reported revenue

    741,214

     

    1,027,910

     

    3,311,822

     

    3,827,808

     

    Revenue purchase accounting adjustments

    205

     

    202

     

    814

     

    2,648

     

    Adjusted revenue

    741,419

     

    1,028,112

     

    3,312,636

     

    3,830,456

     

     
    Reported operating income from continued operations

    137,469

     

    299,847

     

    742,699

     

    1,258,457

     

    OP%

    18.5

    %

    29.2

    %

    22.4

    %

    32.9

    %

    Amortization of intangible assets

    90,169

     

    97,923

     

    370,638

     

    256,569

     

    Purchase accounting adjustments

    87

     

    22,186

     

    45,681

     

    40,993

     

    Acquisition and divestiture-related costs

    13,961

     

    8,429

     

    39,826

     

    62,760

     

    Asset impairment

    -

     

    -

     

    -

     

    3,868

     

    Significant litigation matters and settlements

    5

     

    2

     

    (627

    )

    2

     

    Restructuring and other, net

    (1,863

    )

    3,841

     

    13,580

     

    14,358

     

    Adjusted operating income

    239,828

     

    432,228

     

    1,211,797

     

    1,637,007

     

    OP%

    32.3

    %

    42.0

    %

    36.6

    %

    42.7

    %

     
    AES reported revenue

    347,554

     

    336,415

     

    1,298,376

     

    1,239,361

     

     
    AES reported operating income from continued operations

    31,771

     

    10,297

     

    68,413

     

    73,921

     

    OP%

    9.1

    %

    3.1

    %

    5.3

    %

    6.0

    %

    Amortization of intangible assets

    -

     

    7,638

     

    16,984

     

    33,664

     

    Purchase accounting adjustments

    -

     

    295

     

    6

     

    295

     

    Acquisition and divestiture-related costs

    30,176

     

    8,581

     

    77,212

     

    23,647

     

    AES depreciation addback

    (3,545

    )

    -

     

    (5,908

    )

    -

     

    Significant litigation matters and settlements

    -

     

    101

     

    -

     

    101

     

    Restructuring and other, net

    (425

    )

    (427

    )

    12,706

     

    2,074

     

    AES Adjusted operating income

    57,977

     

    26,485

     

    169,413

     

    133,702

     

    OP%

    16.7

    %

    7.9

    %

    13.0

    %

    10.8

    %

     
    Combined reported revenue

    1,088,768

     

    1,364,325

     

    4,610,198

     

    5,067,169

     

    Revenue purchase accounting adjustments

    205

     

    202

     

    814

     

    2,648

     

    Combined adjusted revenue

    1,088,973

     

    1,364,527

     

    4,611,012

     

    5,069,817

     

     
    Combined operating income from continued operations

    169,240

     

    310,144

     

    811,112

     

    1,332,378

     

    OP%

    15.5

    %

    22.7

    %

    17.6

    %

    26.3

    %

    Amortization of intangible assets

    90,169

     

    105,561

     

    387,622

     

    290,233

     

    Purchase accounting adjustments

    87

     

    22,481

     

    45,687

     

    41,288

     

    Acquisition and divestiture-related costs

    44,137

     

    17,010

     

    117,038

     

    86,407

     

    AES depreciation addback

    (3,545

    )

    -

     

    (5,908

    )

    -

     

    Asset impairment

    -

     

    -

     

    -

     

    3,868

     

    Significant litigation matters and settlements

    5

     

    103

     

    (627

    )

    103

     

    Restructuring and other, net

    (2,288

    )

    3,414

     

    26,286

     

    16,432

     

    Combined adjusted operating income

    297,805

     

    458,713

     

    1,381,210

     

    1,770,709

     

    OP%

    27.3

    %

    33.6

    %

    30.0

    %

    34.9

    %

     
    Combined DAS Revenue and Segment Operating Income
     
    Combined DAS

    694,979

     

    654,913

     

    2,591,285

     

    2,137,079

     

    Diagnostics

    393,994

     

    709,614

     

    2,019,727

     

    2,932,738

     

    Revenue purchase accounting adjustments

    (205

    )

    (202

    )

    (814

    )

    (2,648

    )

    Combined revenue

    1,088,768

     

    1,364,325

     

    4,610,198

     

    5,067,169

     

     
     
    Combined DAS

    203,559

     

    143,873

     

    672,656

     

    415,304

     

    29.3

    %

    22.0

    %

    26.0

    %

    19.4

    %

    Diagnostics

    113,004

     

    334,540

     

    781,985

     

    1,432,769

     

    28.7

    %

    47.1

    %

    38.7

    %

    48.9

    %

    Corporate

    (18,758

    )

    (19,700

    )

    (73,431

    )

    (77,364

    )

    Subtotal reportable segments combined with AES

    297,805

     

    458,713

     

    1,381,210

     

    1,770,709

     

     
    Amortization of intangible assets

    (90,169

    )

    (105,561

    )

    (387,622

    )

    (290,233

    )

    Purchase accounting adjustments

    (87

    )

    (22,481

    )

    (45,687

    )

    (41,288

    )

    Acquisition and divestiture-related costs

    (44,137

    )

    (17,010

    )

    (117,038

    )

    (86,407

    )

    AES depreciation addback

    3,545

     

    -

     

    5,908

     

    -

     

    Asset impairment

    -

     

    -

     

    -

     

    (3,868

    )

    Significant litigation matters and settlements

    (5

    )

    (103

    )

    627

     

    (103

    )

    Restructuring and other, net

    2,288

     

    (3,414

    )

    (26,286

    )

    (16,432

    )

    Combined operating income from continued operations

    169,240

     

    310,144

     

    811,112

     

    1,332,378

     

     
     

    REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

     
    PerkinElmer, Inc. and Subsidiaries

    CONDENSED CONSOLIDATED BALANCE SHEETS

     
     
     
    (In thousands)

    January 1, 2023

    January 2, 2022

     
    Current assets:
    Cash and cash equivalents

    $

    454,358

    $

    603,320

    Accounts receivable, net

     

    612,780

     

    707,941

    Inventories, net

     

    405,462

     

    425,890

    Other current assets

     

    122,254

     

    148,255

    Current assets of discontinued operations

     

    1,702,967

     

    555,374

    Total current assets

     

    3,297,821

     

    2,440,780

     
    Property, plant and equipment, net

     

    482,950

     

    485,531

    Operating lease right-of-use assets

     

    188,351

     

    164,040

    Intangible assets, net

     

    3,377,174

     

    3,821,847

    Goodwill

     

    6,481,768

     

    6,627,119

    Other assets, net

     

    298,787

     

    312,887

    Long-term assets of discontinued operations

     

    -

     

    1,148,350

    Total assets

    $

    14,126,851

    $

    15,000,554

     
    Current liabilities:
    Current portion of long-term debt

    $

    470,929

    $

    4,240

    Accounts payable

     

    272,826

     

    324,811

    Accrued expenses and other current liabilities

     

    578,301

     

    679,099

    Current liabilities of discontinued operations

     

    244,448

     

    205,594

    Total current liabilities

     

    1,566,504

     

    1,213,744

     
    Long-term debt

     

    3,923,347

     

    4,979,737

    Long-term liabilities

     

    1,072,120

     

    1,422,549

    Operating lease liabilities

     

    169,968

     

    147,395

    Long-term liabilities of discontinued operations

     

    2,036

     

    95,884

    Total liabilities

     

    6,733,975

     

    7,859,309

     
    Total stockholders' equity

     

    7,392,876

     

    7,141,245

    Total liabilities and stockholders' equity

    $

    14,126,851

    $

    15,000,554

     
     
    PREPARED IN ACCORDANCE WITH GAAP
     
    PerkinElmer, Inc. and Subsidiaries

    CONSOLIDATED STATEMENTS OF CASH FLOWS

     
     

    Three Months Ended

    Twelve Months Ended

    January 1, 2023

    January 2, 2022

    January 1, 2023

    January 2, 2022

    (In thousands)

    (In thousands)

     
    Operating activities:
    Net income

    $

    137,658

     

    $

    190,184

     

    $

    579,179

     

    $

    943,157

     

    Income from discontinued operations and dispositions, net of income taxes

     

    (30,161

    )

     

    (6,095

    )

     

    (56,503

    )

     

    (53,721

    )

    Income from continuing operations

     

    107,497

     

     

    184,089

     

     

    522,676

     

     

    889,436

     

    Adjustments to reconcile income from continuing operations to net cash provided by continuing operations:
    Restructuring and other, net

     

    (1,863

    )

     

    3,841

     

     

    13,580

     

     

    14,358

     

    Depreciation and amortization

     

    104,234

     

     

    114,057

     

     

    427,000

     

     

    311,443

     

    Stock-based compensation

     

    11,742

     

     

    12,994

     

     

    51,518

     

     

    29,675

     

    Pension and other postretirement income

     

    (22,464

    )

     

    (29,214

    )

     

    (23,104

    )

     

    (28,509

    )

    Change in fair value of contingent consideration

     

    (608

    )

     

    1,566

     

     

    (1,377

    )

     

    3,119

     

    Amortization of deferred debt financing costs and accretion of discounts

     

    1,264

     

     

    1,738

     

     

    7,310

     

     

    4,962

     

    Gain on disposition of businesses and assets, net

     

    (2,887

    )

     

    -

     

     

    (2,887

    )

     

    (1,970

    )

    Change in fair value of financial securities

     

    1,433

     

     

    (2,419

    )

     

    15,754

     

     

    (10,985

    )

    Debt extinguishment gain

     

    (2,788

    )

     

    -

     

     

    (2,880

    )

     

    -

     

    Amortization of acquired inventory revaluation

     

    250

     

     

    20,473

     

     

    45,289

     

     

    35,201

     

    Asset impairment

     

    -

     

     

    -

     

     

    -

     

     

    3,868

     

    Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:
    Accounts receivable, net

     

    (54,044

    )

     

    (66,334

    )

     

    66,093

     

     

    165,590

     

    Inventories

     

    (4,159

    )

     

    13,098

     

     

    (48,634

    )

     

    32,280

     

    Accounts payable

     

    (15,837

    )

     

    32,406

     

     

    (43,804

    )

     

    (7,577

    )

    Accrued expenses and other

     

    (8,105

    )

     

    49,833

     

     

    (355,761

    )

     

    (110,707

    )

    Net cash provided by operating activities of continuing operations

     

    113,665

     

     

    336,128

     

     

    670,773

     

     

    1,330,184

     

    Net cash provided by (used in) operating activities of discontinued operations

     

    25,493

     

     

    (537

    )

     

    9,037

     

     

    80,566

     

    Net cash provided by operating activities

     

    139,158

     

     

    335,591

     

     

    679,810

     

     

    1,410,750

     

     
    Investing activities:
    Capital expenditures

     

    (26,130

    )

     

    (26,954

    )

     

    (85,632

    )

     

    (86,020

    )

    Purchases of investments

     

    (7,166

    )

     

    (4,000

    )

     

    (47,181

    )

     

    (23,130

    )

    Proceeds from notes receivables

     

    -

     

     

    -

     

     

    8,890

     

     

    -

     

    Proceeds from surrender of life insurance policies

     

    -

     

     

    109

     

     

    -

     

     

    109

     

    Proceeds from disposition of businesses and assets

     

    8,842

     

     

    -

     

     

    14,505

     

     

    1,460

     

    Cash paid for acquisitions, net of cash acquired

     

    -

     

     

    (17,008

    )

     

    (7,518

    )

     

    (3,982,216

    )

    Net cash used in investing activities of continuing operations

     

    (24,454

    )

     

    (47,853

    )

     

    (116,936

    )

     

    (4,089,797

    )

    Net cash used in investing activities of discontinued operations

     

    (1,229

    )

     

    (12,097

    )

     

    (15,915

    )

     

    (22,961

    )

    Net cash used in investing activities

     

    (25,683

    )

     

    (59,950

    )

     

    (132,851

    )

     

    (4,112,758

    )

     
    Financing Activities:
    Payments on borrowings

     

    (20,000

    )

     

    (368,008

    )

     

    (240,000

    )

     

    (1,559,133

    )

    Proceeds from borrowings

     

    20,000

     

     

    256,000

     

     

    240,000

     

     

    1,400,282

     

    Proceeds from term loan

     

    -

     

     

    -

     

     

    -

     

     

    500,000

     

    Payments of term loan

     

    -

     

     

    -

     

     

    (500,000

    )

     

    -

     

    Payments of senior debt

     

    (50,404

    )

     

    -

     

     

    (57,876

    )

     

    (339,605

    )

    Proceeds from sale of senior debt

     

    -

     

     

    -

     

     

    -

     

     

    3,086,095

     

    Payments of debt financing costs

     

    -

     

     

    -

     

     

    -

     

     

    (30,983

    )

    Settlement of cash flow hedges

     

    -

     

     

    (3,023

    )

     

    (762

    )

     

    (4,482

    )

    Settlement of swaps

     

    -

     

     

    (14,314

    )

     

    -

     

     

    (14,314

    )

    Net payments on other credit facilities

     

    (811

    )

     

    (938

    )

     

    (1,292

    )

     

    (13,670

    )

    Payments for acquisition-related contingent consideration

     

    -

     

     

    (2,208

    )

     

    (5

    )

     

    (2,208

    )

    Proceeds from issuance of common stock under stock plans

     

    7,861

     

     

    2,360

     

     

    14,114

     

     

    25,120

     

    Purchases of common stock

     

    (24,501

    )

     

    (60

    )

     

    (80,638

    )

     

    (73,072

    )

    Dividends paid

     

    (8,841

    )

     

    (8,834

    )

     

    (35,344

    )

     

    (32,373

    )

    Net cash (used in) provided by financing activities of continuing operations

     

    (76,696

    )

     

    (139,025

    )

     

    (661,803

    )

     

    2,941,657

     

    Net cash (used in) provided by financing activities of discontinued operations

     

    -

     

     

    -

     

     

    -

     

     

    -

     

    Net cash (used in) provided by financing activities

     

    (76,696

    )

     

    (139,025

    )

     

    (661,803

    )

     

    2,941,657

     

     
    Effect of exchange rate changes on cash, cash equivalents, and restricted cash

     

    17,656

     

     

    (6,341

    )

     

    (33,747

    )

     

    (22,926

    )

     
    Net increase (decrease) in cash, cash equivalents, and restricted cash

     

    54,435

     

     

    130,275

     

     

    (148,591

    )

     

    216,723

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    416,311

     

     

    489,062

     

     

    619,337

     

     

    402,614

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    470,746

     

    $

    619,337

     

    $

    470,746

     

    $

    619,337

     

     
     
    Supplemental disclosure of cash flow information:

    Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:

    Cash and cash equivalents

    $

    454,358

     

    $

    603,320

     

    $

    454,358

     

    $

    603,320

     

    Restricted cash included in other current assets

     

    1,040

     

     

    1,018

     

     

    1,040

     

     

    1,018

     

    Restricted cash included in other assets

     

    349

     

     

    -

     

     

    349

     

     

    -

     

    Cash and cash equivalents included in current assets of discontinued operations

     

    14,999

     

     

    14,999

     

     

    14,999

     

     

    14,999

     

    Total cash, cash equivalents and restricted cash

    $

    470,746

     

    $

    619,337

     

    $

    470,746

     

    $

    619,337

     

     

    PREPARED IN ACCORDANCE WITH GAAP

     
    PerkinElmer, Inc. and Subsidiaries

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

     
     

    Continuing Operations

    Three Months Ended

    January 1, 2023

    Organic revenue growth:
    Reported revenue growth from continuing operations

    -28%

    Less: effect of foreign exchange rates

    -5%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Organic revenue growth from continuing operations

    -23%

    Less: effect of COVID products

    -31%

    Non-COVID organic revenue growth from continuing operations

    8%

     
     

    Combined PKI

    Three Months Ended

    January 1, 2023

    Combined organic revenue growth:
    Reported revenue growth from continuing operations

    -28%

    Plus: effect of discontinued operations

    8%

    Less: effect of foreign exchange rates

    -5%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Combined organic revenue growth

    -15%

    Less: effect of COVID products

    -23%

    Combined non-COVID organic revenue growth

    8%

     
     

    DAS

    Three Months Ended

    January 1, 2023

    Organic revenue growth:
    Reported revenue growth continuing operations

    9%

    Less: effect of foreign exchange rates

    -4%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Organic revenue growth from continuing operations

    13%

     
     

    Combined DAS

    Three Months Ended

    January 1, 2023

    Combined organic revenue growth:
    Reported revenue growth from DAS continuing operations

    9%

    Plus: effect of discontinued operations

    -3%

    Less: effect of foreign exchange rates

    -5%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Combined organic revenue growth

    11%

     
     

    Diagnostics

    Three Months Ended

    January 1, 2023

    Organic revenue growth:
    Reported revenue growth continuing operations

    -44%

    Less: effect of foreign exchange rates

    -5%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Organic revenue growth from continuing operations

    -39%

     
    (1) amounts may not sum due to rounding
    PerkinElmer, Inc. and Subsidiaries

    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)

     
     

    DAS

    Twelve Months Ended

    January 1, 2023

    Organic revenue growth:
    Reported revenue growth continuing operations

    44%

    Less: effect of foreign exchange rates

    -4%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    32%

    Organic revenue growth from continuing operations

    15%

     
     

    Combined DAS

    Twelve Months Ended

    January 1, 2023

    Combined organic revenue growth:
    Reported revenue growth from DAS continuing operations

    44%

    Plus: effect of discontinued operations

    -23%

    Less: effect of foreign exchange rates

    -4%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    14%

    Combined organic revenue growth

    12%

     
     

    Diagnostics

    Twelve Months Ended

    January 1, 2023

    Organic revenue growth:
    Reported revenue growth continuing operations

    -31%

    Less: effect of foreign exchange rates

    -4%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    2%

    Organic revenue growth from continuing operations

    -29%

     
    (1) amounts may not sum due to rounding

    Explanation of Non-GAAP Financial Measures

    We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

    We use the term "adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "adjusted revenue growth" to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

    We use the term "combined adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules and including revenue from the AES business reported in discontinued operations. We use the related term "combined adjusted revenue growth" to refer to the measure of comparing current period combined adjusted revenue with the corresponding period of the prior year.

    We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

    We use the term "combined organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules and including revenue from the AES business reported in discontinued operations. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "combined non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

    We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of adjusted revenue.

    We use the term "combined adjusted gross margin" to refer to GAAP gross margin, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "combined adjusted gross margin percentage" to refer to combined adjusted gross margin as a percentage of combined adjusted revenue.

    We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of adjusted revenue.

    We use the term "combined adjusted SG&A expense" to refer to GAAP SG&A expense, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "combined adjusted SG&A percentage" to refer to combined adjusted SG&A expense as a percentage of combined adjusted revenue.

    We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of adjusted revenue.

    We use the term "combined adjusted R&D expense" to refer to GAAP R&D expense, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "combined adjusted R&D percentage" to refer to combined adjusted R&D expense as a percentage of combined adjusted revenue.

    We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in the value of financial securities and debt extinguishment costs.

    We use the term "adjusted operating income," to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," or "adjusted operating margin" to refer to adjusted operating income as a percentage of adjusted revenue.

    We use the term "combined adjusted operating income," to refer to GAAP operating income, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "combined adjusted operating profit percentage," "combined adjusted operating profit margin," or "combined adjusted operating margin" to refer to combined adjusted operating income as a percentage of combined adjusted revenue.

    We use the term "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    We use the term "combined adjusted earnings per share," or "combined adjusted EPS," to refer to GAAP earnings per share, adjusted for the inclusion of the AES business reported in discontinued operations and including the depreciation of long-lived assets that is ceased upon reporting the business as held for sale. Additional adjustments include: including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

    • Amortization of intangible assets— purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
    • Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules— accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
    • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
    • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest expense, foreign exchange gains and losses, integration expenses and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Acceleration of executive compensation—the announced retirement of a senior executive resulted in an acceleration of compensation expense. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
    • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
    • Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Impact of foreign currency changes on the current period— we exclude the impact of foreign currency from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
    • Impact of significant tax events—we exclude the impact of significant tax events, such as the Tax Cuts and Jobs Act of 2017. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
    • Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Inclusion of the AES business in combined information—we report the results of the AES business in discontinued operations and include those results as a component of combined information. Management believes that including the results of the AES business in discontinued operations as a component of combined information increases the comparability of the financial results with historically presented results as well as recent forecasts.
    • Depreciation of fixed assets ceased upon reporting the business as held for sale—we exclude the impact of ceasing depreciation of fixed assets that are held for sale. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such expenses were ceased.

    The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, acceleration of executive compensation, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

    The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

    Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230214005052/en/

    Get the next $PKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PKI

    DatePrice TargetRatingAnalyst
    12/19/2022$170.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/12/2022$135.00 → $170.00Neutral → Buy
    Citigroup
    12/6/2022$192.00 → $164.00Market Perform → Outperform
    Cowen
    11/28/2022$130.00 → $145.00Underweight → Equal Weight
    Barclays
    8/25/2022$175.00Neutral
    Credit Suisse
    8/18/2022$190.00 → $170.00Buy → Hold
    Stifel
    8/2/2022$178.00Buy → Neutral
    BofA Securities
    7/20/2022$160.00Buy
    UBS
    More analyst ratings

    $PKI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Revvity Announces Financial Results for the First Quarter of 2023

      Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

      5/11/23 6:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

       Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

      5/9/23 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Ares Management Corporation Announces U.S. Direct Lending Origination Activity for the First Quarter and Last Twelve Months 2023

      Approximately $2.1 Billion in New Commitments Closed in the First Quarter and Approximately $23.5 Billion closed in the Last Twelve Months Ended March 31, 2023 Ares Management Corporation announced today that funds managed by its Credit Group (collectively "Ares") closed approximately $2.1 billion in U.S. direct lending commitments across 35 transactions during the first quarter of 2023 and approximately $23.5 billion in U.S. direct lending commitments across 189 transactions in the last twelve-month period ended March 31, 2023. Below is a description of selected transactions that Ares closed during the first quarter. Banyan Software Ares served as the agent, lead arranger and bookrun

      4/28/23 6:30:00 AM ET
      $ARES
      $PKI
      Investment Managers
      Finance
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    SEC Filings

    See more
    • PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      2/1/24 6:05:15 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Inc. filed SEC Form 8-K: Leadership Update

      8-K - REVVITY, INC. (0000031791) (Filer)

      1/26/24 8:00:33 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - REVVITY, INC. (0000031791) (Filer)

      1/9/24 8:05:29 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Financials

    Live finance-specific insights

    See more
    • Revvity Announces Financial Results for the First Quarter of 2023

      Revenue of $675 million; (30)% reported growth; (27)% organic growth; 6% non-COVID organic growth GAAP EPS of $4.50; Adjusted EPS from continuing operations of $1.01 Updates full year 2023 guidance Authorizes new $600 million share repurchase program To begin trading under new ticker "RVTY" on May 16th Revvity, Inc. (NYSE:PKI), today reported financial results for the first quarter ended April 2, 2023. The Company reported GAAP earnings per share of $4.50, as compared to $1.40 in the same period a year ago. GAAP revenue for the quarter was $675 million, as compared to $963 million in the same period a year ago. GAAP operating income for the quarter was $76 million, as comp

      5/11/23 6:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure

       Transformation aimed at revolutionizing next generation scientific breakthroughs that solve the world's greatest health challenges Trusted partner to pharma, government and diagnostics customers with complete, end-to-end solutions To begin trading as RVTY under new name on May 16th (NYSE:PKI) Revvity, Inc. officially launches today as a science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere. Born from two words, "revolutionize" (rev) and "vita" (vit) meaning "life" in Latin, Revvity delivers end-to-end expertise and solutions from research discovery to development, and diagnosis to cure. The Company was prev

      5/9/23 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Board Declares Quarterly Dividend

      The Board of Directors of PerkinElmer, Inc. (NYSE:PKI) today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 11, 2023 to all shareholders of record at the close of business on July 21, 2023. About The PerkinElmer Life Sciences and Diagnostics Company The PerkinElmer Life Sciences and Diagnostics company – which is to be renamed during the second quarter of 2023 – provides end-to-end solutions that help scientists, researchers and clinicians better diagnose disease and discover new and more personalized drugs. The Company reported revenues of approximately $3.3 billion in 2022, serves customers in 190 countries, and is a compon

      4/25/23 4:05:00 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/14/24 4:11:39 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/14/24 10:04:34 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by PerkinElmer Inc. (Amendment)

      SC 13G/A - REVVITY, INC. (0000031791) (Subject)

      2/13/24 5:13:53 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gonzales Anita covered exercise/tax liability with 119 shares, decreasing direct ownership by 3% to 3,591 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 5:33:35 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Krakowiak Maxwell covered exercise/tax liability with 85 shares, decreasing direct ownership by 1% to 7,117 units (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 5:09:03 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Klobuchar Michael A was granted 481 shares (SEC Form 4)

      4 - REVVITY, INC. (0000031791) (Issuer)

      2/16/24 4:05:16 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Leadership Updates

    Live Leadership Updates

    See more
    • James Mock Joins Moderna as Chief Financial Officer

      CAMBRIDGE, MA / ACCESSWIRE / August 17, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that James Mock has been appointed as Moderna's Chief Financial Officer, beginning September 6, 2022. He will serve on Moderna's Executive Committee and report to Chief Executive Officer Stéphane Bancel. Following the appointment of Mr. Mock, David Meline will retire as the Company's CFO effective the same date but will remain as a consultant to the Company to assist with the transition."I am thrilled to welcome Jamey to Moderna's Executive Committee as our Chief Financial Officer. Moderna is at an exciting stage with a

      8/17/22 8:00:00 AM ET
      $MRNA
      $PKI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Announces Finance Leadership Transition

      Max Krakowiak appointed new chief financial officer, replacing Jamey Mock PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Senior Vice President and Chief Financial Officer Jamey Mock will be transitioning from the Company to pursue an outside opportunity. The Company's Board of Directors has unanimously appointed Max Krakowiak to succeed Mr. Mock as its new senior vice president and CFO, effective as of September 6, 2022. Mr. Krakowiak is currently the Company's vice president of corporate finance, and has served in financial leadership roles of increasing responsibility for the last four years. "I would like to thank Jamey

      8/17/22 8:00:00 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer Provides First Quarter Update and Schedules Earnings Call for Tuesday, May 4, 2021

       Company also announces appointment of Steve Willoughby as vice president, investor relations PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates reported and organic revenue growth of 98% and 90%, respectively, for the first quarter ended April 4, 2021. PerkinElmer's strong revenue performance was driven by broad-based momentum across the portfolio. In total, non-COVID-19, or core, demand increased approximately 10% organically year-over-year, and COVID-19 related solutions contributed approximately $535 million of revenue in the first quarter. PerkinElmer will release its first quarter 2021 financial results a

      4/13/21 4:15:00 PM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PKI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PerkinElmer upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded PerkinElmer from Sector Weight to Overweight and set a new price target of $170.00

      12/19/22 7:48:08 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer upgraded by Citigroup with a new price target

      Citigroup upgraded PerkinElmer from Neutral to Buy and set a new price target of $170.00 from $135.00 previously

      12/12/22 7:52:36 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PerkinElmer upgraded by Cowen with a new price target

      Cowen upgraded PerkinElmer from Market Perform to Outperform and set a new price target of $164.00 from $192.00 previously

      12/6/22 7:47:47 AM ET
      $PKI
      Biotechnology: Laboratory Analytical Instruments
      Industrials